First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 50 条
  • [1] First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study
    Cheng, Y.
    Fan, Y.
    Zhao, Y.
    Huang, D.
    Li, X.
    Zhang, P.
    Kang, M.
    Yang, N.
    Zhong, D.
    Wang, Z.
    Yu, Y.
    Zhang, Y.
    Zhao, J.
    Qin, T.
    Chen, C.
    Leaw, S.
    Zheng, W.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S46 - S46
  • [2] First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis
    Long, Rong
    Chen, Fangping
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [3] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
    Horn, L.
    Mansfield, A. S.
    Szczesna, A.
    Havel, L.
    Krzakowski, M.
    Hochmair, M. J.
    Huemer, F.
    Losonczy, G.
    Johnson, M. L.
    Nishio, M.
    Reck, M.
    Mok, T.
    Lam, S.
    Shames, D. S.
    Liu, J.
    Ding, B.
    Lopez-Chavez, A.
    Kabbinavar, F.
    Lin, W.
    Sandler, A.
    Liu, S. V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23): : 2220 - 2229
  • [4] Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China
    Zhao, Shan
    Kang, Shuo
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025,
  • [5] First-line apatinib plus chemotherapy in extensive-stage small-cell lung cancer.
    Shi, Jian
    Liu, Jiayin
    Duan, Xiaoyang
    Huang, Guanglei
    Wang, Lixing
    Zhao, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer
    West, W
    Birch, R
    Schnell, F
    Hainsworth, J
    Tongol, J
    Campos, L
    ONCOLOGIST, 2003, 8 (01): : 76 - 82
  • [7] Anlotinib Plus Standard Chemotherapy as First-line Treatment in Extensive-Stage Small Cell Lung Cancer Patients
    Zhang, W.
    Yang, H.
    Kong, T.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S536 - S536
  • [8] Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer
    Zhang, Dou
    Kong, Fanming
    Gao, Fangfang
    Li, Longhui
    Liang, Yangyueying
    Yu, Minghui
    Zhao, Lu
    Wang, Na
    Jia, Yingjie
    HELIYON, 2024, 10 (01)
  • [9] Anlotinib plus standard chemotherapy as first-line treatment in extensive-stage small cell lung cancer patients
    Zhang, W.
    Yang, H.
    Kong, T.
    Han, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
  • [10] Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer The Phase 3 EXTENTORCH Randomized Clinical Trial
    Cheng, Ying
    Zhang, Wei
    Wu, Lin
    Zhou, Caicun
    Wang, Donglin
    Xia, Bing
    Bi, Minghong
    Fu, Xiuhua
    Li, Chong
    Lv, Dongqing
    Zhao, Yanqiu
    Chen, Gongyan
    Yi, Tienan
    Huang, Jianan
    Li, Min
    Yang, Runxiang
    Huang, Xiaoping
    Wang, Ye
    Zhang, Mingjun
    Pan, Yueyin
    Sun, Yilan
    Hu, Sheng
    Zhang, Xiqin
    Zhou, Min
    Fang, Jian
    Jin, Faguang
    Liu, Yunpeng
    Li, Yinyin
    Zhang, Zhihong
    Hu, Jie
    Liu, Laiyu
    Wang, Rui
    Li, Yan
    Gu, Kangsheng
    Ding, Cuimin
    Fan, Qingxia
    Zhang, Guojun
    Chen, Yongxing
    Jiang, Liyan
    Zheng, Wei-E.
    Chen, Shaoshui
    Huang, Cheng
    Han, Zhigang
    Yang, Hong
    Wang, Jianfang
    Wang, Baocheng
    Wu, Huita
    Bao, Yongxing
    Li, Manxiang
    Luo, Xianming
    JAMA ONCOLOGY, 2025, 11 (01) : 16 - 25
12345